The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug ...

NICE recommends natalizumab as a new treatment for adults with highly active relapsing-remitting multiple sclerosis ...

NICE has recommended natalizumab for adults with highly active RRMS, citing pregnancy suitability, biosimilar value and NHS ...

NICE has recommended Tysabri and biosimilar Tyruko as an option for patients with highly active relapsing-remitting multiple ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will impact their patients. Dr ...

England's NICE is recommending natalizumab, sold as Tysabri and Tyruko, as an NHS-covered treatment option for people with ...

Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis (MS), suggest phase II study findings showing its efficacy in controlling inflammatory activity ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

Disability progression independent of relapse activity (PIRA) -- sometimes referred to as silent progression -- is a key integrating concept in the contemporary view of multiple sclerosis (MS). "The ...